ストックスクリーナーアプリを入手
14.84
3.82%
-0.59
前日終値:
$15.43
開ける：
$14.99
24時間の取引高:
103.84K
Relative Volume:
1.07
時価総額：
$2.88B
収益：
$630.20M
当期純損益:
$37.73M
株価収益率:
74.20
EPS:
0.2
ネットキャッシュフロー:
$-17.44M
1週間 パフォーマンス:
-12.19%
1か月 パフォーマンス:
+11.83%
6か月 パフォーマンス:
+3.70%
1年 パフォーマンス:
-14.02%
1日の値動き範囲:
$14.70
$15.02
1週間の範囲:
$14.70
$16.89
52週間の値動き範囲:
$11.51
$21.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
HCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.84 | 2.88B | 630.20M | 37.73M | -17.44M | 0.20 |
|
RGC
Regencell Bioscience Holdings Ltd
|
38.01 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.17 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.41 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.95 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-13 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-11-24 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-05-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-03 | 開始されました | Jefferies | Buy |
| 2020-10-02 | 開始されました | Deutsche Bank | Buy |
| 2020-03-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 開始されました | Goldman | Buy |
| 2019-11-19 | 開始されました | CLSA | Buy |
| 2019-10-23 | 繰り返されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
すべてを表示
Hutchmed China Limited Adr (HCM) 最新ニュース
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Bought by Bank of America Corp DE - Defense World
Public Employees Retirement System of Ohio Has $39,000 Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Two Sigma Investments LP Sells 12,471 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise
Market news - investments.halifax.co.uk
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - The Manila Times
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance
HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewswire Inc.
Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter
CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com
RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Hutchmed China Limited Adr (HCM) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.60%
大文字化:
|
ボリューム (24 時間):